ASCO: 'Breakthrough' drug combo twice as effective for some ovarian cancer patients

5 June 2023

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Researchers hope these results will lead to a new option for patients with advanced low-grade serous ovarian cancer (LGSOC), a rare form of the disease that has a poor response rate to current treatments.

The international RAMP-201 (ENGOTov60-National Cancer Research Institute (NCRI)/GOG3052) study, led by researchers from the UK-based Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, and sponsored by Verastem Oncology (Nasdaq: VSTM), has tested avutometinib (VS-6766) alone and in combination with defactinib in 29 patients with LGSOC. Both drugs are designed to block signals that encourage cancer cells to grow.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK